Semaglutide is typically initiated at a low dose and is gradually increased over time
BMJ Case Rep 14(1):e235663
The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )
Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al
Cng thc sn phm khng cha mineral oil hay m thc vt do kem c th thm su vo cc lp di da v pht huy tc dng ti a